News

This week’s edition of The Mainstream Patient features stories about the difference between cold sores and acne, glycerin in skincare, psoriasis and its effect on mental health, how to avoid tech neck, plus more.

ICYMI, some of the content featured this week includes articles about a new adapalene gel for acne vulgaris, if preservatives like parabens are actually safe in cosmetics, characteristics that can help distinguish facial hyperpigmentation disorders, valuable information about vitiligo treatment with expert Seemal R. Desai, M.D., FAAD, plus more.

In this episode, UIC medical students Kayla Clark and Gina Alvarado Jones, along with UIC Dermatology Department Head Maria Tsoukas, M.D. Ph.D., discuss their recently published analysis in JAAD, which takes a look at skin of color representation in medical education.

MC2 Therapeutics and EPI Health announce they have entered into a collaboration agreement for the commercialization of calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064% (Wynzora Cream), a newly U.S. FDA-approved topical treatment for plaque psoriasis in adults.

Alembic Pharmaceuticals announces the launch of their bioequivalent and therapeutically equivalent product to Differin Gel 0.3% (Galderma), Adapalene Gel USP 0.3%, a topical retinoid for the treatment of acne vulgaris in patients 12 years and older.

Vitiligo can be psychologically devastating for patients. Expert Seemal R. Desai, M.D., FAAD, shares how recent advances in vitiligo treatment offer hope to patients impacted by the disease.

While several employees wanted to wear masks upon his office reopening, Dr. Covid reminded them that their state governor and city mayor did not require their use. Now an employee has contracted COVID-19 from a patient and has filed a complaint with the Occupational Safety and Health Administration. Should he be concerned?

This week’s edition of The Mainstream Patient features stories about a newly approved acne treatment, strawberry legs, coconut oil in skincare, if your acne might possibly be rosacea, plus more

Subtypes such as confetti vitiligo and trichrome vitiligo can be signs of unstable active disease, says expert Seemal R. Desai, M.D., FAAD.

ICYMI, some of the content featured this week includes articles about emerging options for high-risk melanoma, a new FDA-approved topical androgen receptor inhibitor for treatment of acne vulgaris, a glimpse into the world of vitiligo treatment with expert Seemal R. Desai, M.D., FAAD, plus more.

Clascoterone cream 1% (Winlevi, Cassiopea), a first-in-class androgen receptor inhibitor, has been approved by the U.S. FDA for treatment of acne vulgaris in patients 12 years and older.

Expert Seemal R. Desai, M.D., FAAD, highlights new therapeutics that may impact the future of vitiligo management, a topic he discussed at the AAD Virtual Meeting Experience (VMX) in June.

Antioxidants can be a valuable part of your vitiligo therapeutic armamentarium, says expert Seemal R. Desai, M.D., FAAD.

Dermavant announces positive results from its two identical phase 3 trials investigating tapinarof cream 1% for treatment of plaque psoriasis in adult patients.

Manipulating the microbiome has been shown to impact conditions including acne, atopic dermatitis (AD), autoimmune diseases and melanoma. While there are many clinical trials now in progress, safety and efficacy have not yet been proven.

Eli Lilly’s mirikizumab demonstrates superiority over secukinumab (Cosentyx, Novartis) as a treatment for moderate-to-severe plaque psoriasis, according to recently released results from the OASIS-2 study.

Expert Seemal R. Desai, M.D., FAAD, offers practical tips for stabilizing patients who present with active, spreading vitiligo, a topic he discussed at the AAD Virtual Meeting Experience (VMX) in June.

Researchers at Mount Sinai Medical Center are investigating interactions between immunomodulatory treatments used to manage inflammatory skin diseases and the effects on patients with COVID-19.

Is your patient’s vitiligo stable, unstable or recalcitrant? Expert Seemal R. Desai, M.D., FAAD, discusses how he classifies disease activity in his practice.

This week’s edition of The Mainstream Patient features stories about viral exfoliating body washcloths, hyaluronic acid, wearing sunscreen with a mask, body acne, plus more.

Expert Seemal R. Desai, M.D., FAAD, stresses the importance of defining treatment goals when meeting with vitiligo patients, a topic he covered during his presentation at the AAD Virtual Meeting Experience (VMX) in June.

ICYMI, some of the content featured this week includes a new episode of our podcast on how to become a pediatric dermatologist, tape strips that can detect psoriasis and eczema biomarkers, latest results of a phase 2b trial investigating phosphodiesterase for psoriasis, skin findings in patients with COVID-19, plus more.

The International Society of Hair Restoration Surgery (ISHRS) has decided to move their 2020 world congress online, taking place Oct. 17-25. The world congress was initially supposed to be held in person in Panama.

This episode discusses how to become a pediatric dermatologist, including the associated benefits, compensation and responsibilities with Heather Brandling-Bennett, M.D.

BIOTOC, a noninvasive alternative to injectables skincare line from k-beauty company Dermafirm Inc., has launched in the U.S.

This week’s edition of The Mainstream Patient features stories about hair loss and COVID-19, natural deodorant rashes, cortisone shots for acne, CVS removing octinoxate and oxybenzone from its store-brand sunscreens, plus more.

Geneticist Thomas M. Hitchcock, Ph.D., explores the relationship between skin and its microbes. Through a series of interviews with dermatology experts, he shares insight into what is the skin microbiome and why it is critical to skin health.

ICYMI, some of the content featured this week includes combination treatments for keloids, inflammatory pathways involved in rosacea pathogenesis, using smartphones to improve GEA scale assessment in patients with darker skin types, the use of artificial intelligence for evaluating acne severity, plus more.

AbbVie announces the launch of their hidradenitis suppurativa-centered educational website aimed at bringing awareness and educating physicians on the disease.

A Danish dermatology company releases their new HIFU device, TOOsonix System ONE-M, for treatment of color-independent tattoo removal, spider veins, lentigines, telangiectasia, angiomas and various other aesthetic conditions.